Provectus Biopharmaceuticals annual revenue
2011
2012
2013
2014
2015
2022
2023
2024
2025
Provectus Biopharmaceuticals Revenue Growth & History (PVCT)
Provectus Biopharmaceuticals reported $336,108 in revenue for fiscal 2025, a decrease of 45.54% from the previous fiscal year.
View full Provectus Biopharmaceuticals company overviewProvectus Biopharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $336,108 | −$281,032 | −45.54% |
| 2024 | 2024-12-31 | $617,140 | $59,430 | +10.66% |
| 2023 | 2023-12-31 | $557,710 | −$431,332 | −43.61% |
| 2022 | 2022-12-31 | $989,042 | $989,042 | — |
| 2015 | 2015-12-31 | $0 | $0 | — |
| 2014 | 2014-12-31 | $0 | $0 | — |
| 2013 | 2013-12-31 | $0 | $0 | — |
| 2012 | 2012-12-31 | $0 | $0 | — |
| 2011 | 2011-12-31 | $0 | — | — |
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Primary source
SEC company filings
TickerStat standardizes reported company facts from SEC EDGAR. Derived growth rates use the displayed revenue values and are not company guidance or forecasts.
Review Provectus Biopharmaceuticals filings at SEC.gov ↗